碳青霉烯类耐药肠杆菌科细菌临床检测与治疗方案的发展及应用

doi:10.3969/j.issn.1673-8640.2020.10.001

摘要/Abstract

摘要：

随着广谱抗菌药物的超负荷应用,以碳青霉烯类耐药肠杆菌科细菌（CRE）为代表的多重耐药菌快速播散,成为临床抗感染治疗的巨大挑战。“碳青霉烯类耐药肠杆菌科细菌临床检测与治疗方案的发展及应用”专题汇集了CRE相关热点的4篇论著和2篇综述,分别阐述了CRE不同的检测方法和治疗策略,为临床CRE的诊疗和防控了提供重要的参考依据。

关键词: 碳青霉烯类, 肠杆菌科, 耐药, 检测, 治疗

Abstract:

With the overload use of broad-spectrum antibacterial drugs,multi-drug resistant bacteria,represented by carbapenem-resistant Enterobacteriaceae（CRE）,have been rapidly spread,which has greatly threaten clinical anti-infection treatment. In this issue "The development and application of clinical determination and treatment for carbapenem-resistant Enterobacteriaceae",4 original articles and 2 reviews introduce different determination techniques and treatment strategies of CRE,which provides a reference for clinical diagnosis,treatment and prevention of CRE.

Key words: Carbapenem, Enterobacteriaceae, Drug resistance, Determination, Treatment

中图分类号:

R446.5

王粟, 赵虎. 碳青霉烯类耐药肠杆菌科细菌临床检测与治疗方案的发展及应用[J]. 检验医学, 2020, 35(10): 967-970.

WANG Su, ZHAO Hu. Development and application of clinical determination and treatment for carbapenem-resistant Enterobacteriaceae[J]. Laboratory Medicine, 2020, 35(10): 967-970.

参考文献 23

[1]	徐旋,曲芬. 碳青霉烯耐药的肠杆菌科细菌诊断进展[J]. 生物工程学报,2018,34(8):1338-1345.
[2]	CASSINI A,HÖGBERG L D,PLACHOURAS D,et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015:a population-level modelling analysis[J]. Lancet Infect Dis,2019,19(1):56-66.
[3]	郑少微,李萍,张正良,等. 2005—2017年中国CHINET常见革兰阴性菌对碳青霉烯类抗生素耐药的监测结果[J]. 临床急诊杂志,2019,20(1):40-44.
[4]	GRUNDMANN H,GLASNER C,ALBIGER B,et al.Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae(EuSCAPE):a prospective,multinational study[J]. Lancet Infect Dis,2017,17(2):153-163.
[5]	TZOUVELEKIS LS,MARKOGIANNAKIS A,PSICHOGIOU M,et al.Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae:an evolving crisis of global dimensions[J]. Clin Microbiol Rev,2012,25(4):682-707.
[6]	ZHANG Y,WANG Q,YIN Y,et al.Epidemiology of carbapenem-resistant Enterobacteriaceae infections:report from the China CRE network[J]. Antimicrob Agents Chemother,2018,62(2):e01882-17.
[7]	BUSH K.Carbapenemases:partners in crime[J]. J Glob Antimicrob Res,2013,1(1):7-16.
[8]	TEETHAISONG Y,HOBBS G,NAKOUTI I,et al.A nitrocefin disc supplemented with ertapenem for rapid screening of carbapenemase-producing Enterobacteriaceae[J]. Diagn Microbiol Infect Dis,2018,91(1):85-88.
[9]	ALIZADEH N,REZAEE M A,KAFIL H S,et al.Detection of carbapenem-resistant Enterobacteriaceae by chromogenic screening media[J]. J Microbiol Methods,2018,153:40-44.
[10]	Centers for Disease Control and Prevention.2009. Laboratory protocol for detection of carbapenem-resistant or carbapenemase-producing,Klebsiella spp. and E. coli from rectal swabs[S]. Centers for Disease Control and Prevention,Atlanta,GA.
[11]	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S25,CLSI,2015.
[12]	NORDMANN P,JAYOL A,POIREL L.Rapid detection of polymyxin resistance in Enterobacteriaceae[J]. Emerg Infect Dis,2016,22(6):1038-1043.
[13]	LIAO Q,XIE Y,WANG C,et al.Development and evaluation of the method for detecting metallo-carbapenemases among carbapenemase-producing Enterobacteriaceae[J]. J Microbiol Methods,2019,163:105652.
[14]	VAN DER ZWALUW K,DE HAAN A,PLUISTER G N,et al. The carbapenem inactivation method(CIM),a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods[J]. PLoS One,2015,10(3):e0123690.
[15]	MILLER S,HUMPHRIES R M.Clinical laboratory detection of carbapenem-resistant and carbapenemase-producing Enterobacteriaceae[J]. Expert Rev Anti Infect Ther,2016,14(8):705-717.
[16]	CUI X,ZHANG H,DU H.Carbapenemases in Enterobacteriaceae:detection and antimicrobial therapy[J]. Fron Microbiol,2019,10:1823.
[17]	SHIRLEY M.Ceftazidime-avibactam:a review in the treatment of serious gram-negative bacterial infections[J]. Drugs,2018,78(6):675-692.
[18]	TISCHENDORF J,DE AVILA R A,SAFDAR N. Risk of infection following colonization with carbapenem-resistant Enterobactericeae:a systematic review[J]. Am J Infect Control,2016,44(5):539-543.
[19]	张侃,马琳,王博,等. 耐碳青霉烯肠杆菌科细菌定植与感染研究进展[J]. 国际呼吸杂志,2019,39(10):788-792.
[20]	TACCONELLI E,MAZZAFERRI F,DE SMET A M,et al. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers[J]. Clin Microbiol Infect,2019,25(7):807-817.
[21]	MACHUCA I,GUTIÉRREZ-GUTIÉRREZ B,PÉREZ CORTÉS S,et al. Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant,KPC-producing Klebsiella pneumoniae[J]. J Antimicrob Chemother,2016,71(11):3242-3249.
[22]	BAR-YOSEPH H,HUSSEIN K,BRAUN E,et al.Natural history and decolonization strategies for ESBL/carbapenem-resistant Enterobacteriaceae carriage:systematic review and meta-analysis[J]. J Antimicrob Chemother,2016,71(10):2729-2739.
[23]	DINH A,FESSI H,DURAN C,et al.Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant Enterococci carriage after faecal microbiota transplant:a prospective comparative study[J]. J Hosp Infect,2018,99(4):481-486.